Edition:
United States

Johnson & Johnson (JNJ)

JNJ on New York Consolidated

118.86USD
17 Feb 2017
Change (% chg)

$0.78 (+0.66%)
Prev Close
$118.08
Open
$118.19
Day's High
$118.90
Day's Low
$118.05
Volume
8,691,397
Avg. Vol
7,152,849
52-wk High
$126.07
52-wk Low
$102.23

Latest Key Developments (Source: Significant Developments)

Ethicon announces agreement to acquire Torax Medical
Friday, 17 Feb 2017 10:00am EST 

Ethicon Inc : Ethicon announces agreement to acquire Torax Medical, Inc. .financial terms of transaction have not been disclosed.  Full Article

Swiss Takeover Commission OKs J&J offer for Actelion
Thursday, 16 Feb 2017 03:01am EST 

Actelion Ltd :Swiss Takeover Commission says J&J offer for Actelion meets legal requirements.  Full Article

Renova Therapeutics enters into agreement to receive Stresscopin investigational new drug file from Janssen
Monday, 6 Feb 2017 11:00am EST 

Renova Therapeutics : Enters into agreement to receive Stresscopin investigational new drug file from Janssen . Renova holds an exclusive license to Stresscopin Peptide from nonprofit research development foundation .Plans to advance development of Stresscopin program as RT-400,peptide infusion treatment for episodes of acute decompensated heart failure.  Full Article

BRIEF-J&J says upon termination of transaction agreement, under some circumstances, Actelion may be obligated to pay co a fee
Wednesday, 1 Feb 2017 04:05pm EST 

Corrects source to Johnson & Johnson from Actelion Ltd.Johnson & Johnson :J&J - upon termination of transaction agreement, under some circumstances, Actelion may be obligated to pay co a fee - sec filing.  Full Article

ChemDiv announces multi-year hit identification collaboration with Janssen
Tuesday, 31 Jan 2017 09:00am EST 

Johnson & Johnson - : ChemDiv-Entered into hit identification collaboration with Janssen to identify potent hit series for range of targets across multiple therapeutic areas .ChemDiv- Janssen is granted open-ended access to Chemdiv's discovery chemistry platform.  Full Article

Fitch affirms Johnson & Johnson's IDR at 'AAA'; outlook stable
Friday, 27 Jan 2017 03:42pm EST 

Fitch:Fitch affirms Johnson & Johnson's IDR at 'AAA'; outlook stable.  Full Article

DePuy Synthes receives FDA clearance for cement-augmented pedicle screw systems
Thursday, 26 Jan 2017 10:00am EST 

DePuy Synthes : DePuy Synthes receives FDA clearance for cement-augmented pedicle screw systems .Depuy synthes - Both fenestrated screw systems are anticipated to be available in United States in mid-2017.  Full Article

J&J has two-year agreement on stake in R&D company
Thursday, 26 Jan 2017 09:04am EST 

Johnson & Johnson : J&J says on investor call it has two year agreement not to sell on the open market any equity stake in actelion research and development unit . J&J says won't speculate on how long it will hold stake in research and development company (Reporting By Caroline Humer) ((caroline.humer@thomsonreuters.com;)).  Full Article

Actelion CEO hopes new R&D business to collaborate with J&J on products
Thursday, 26 Jan 2017 08:04am EST 

Actelion : Ceo says new research company to concentrate on development, focus on research for 1-2 years . Ceo says new company to have about 600 employees . Ceo says not sure of success of new company, but "very confident" . Ceo says new company will start with $1 billion in cash, 14 investigational products . Ceo says hopes to collaborate with j&j on products from new research and development company that he will head . Ceo says says will get potential royalties from ms drug, antibiotic from j&j . Ceo says did not speak with shareholder rudolf maag about transaction, "he has read about the deal this morning. I think he's going to like it." . Cfo says says source of cash in new company will be j&j equity stake, cash spun off from actelion demerger into new company . Ceo says nearly no overlap of companies to cause antitrust concerns .CEO says "With this structure it was not difficult. It's always emotional but it's not difficult. Because frankly it's a good solution for everybody.".  Full Article

Jupiter says J&J purchase of Actelion "very good outcome"
Thursday, 26 Jan 2017 06:00am EST 

: Jupiter Fund Manager Mike Buhl-nielsen: Johnson & Johnson purchase of actelion is "very good outcome", says can see "clear synergies for j&j" . Buhl-Nielsen holds Actelion shares Further company coverage: [JNJ.N] [ATLN.S] ((carolyn.cohn@thomsonreuters.com;)).  Full Article

More From Around the Web

Photo

Kraft Heinz bids $143 billion for Unilever in global brand grab

LONDON U.S. food company Kraft Heinz Co made a surprise $143 billion offer for Unilever Plc in a bid to build a global consumer goods giant, although it was flatly rejected on Friday by the maker of Lipton tea and Dove soap. | Video